<DOC>
	<DOC>NCT00926055</DOC>
	<brief_summary>18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques. Therefore, in this study the investigators intend to compare the effect of ezetimibe monotherapy or ezetimibe plus statin combination therapy on the atherosclerosis regression using FDG-PET.</brief_summary>
	<brief_title>Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
	<mesh_term>Deoxyglucose</mesh_term>
	<criteria>hsCRP &gt; 2 mg/L and LDL cholesterol &gt; 130 mm/dL history of cardiovascular disease diabetes uncontrolled hypertension active infection previous antihyperlipidemic agents within 6 months previous steroid or antiinflammatory agents within 6 months liver disease renal disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>high risk patients in atherosclerosis</keyword>
</DOC>